(Q53673760)

17 May 2018

title

A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). (English)

1 reference

17 May 2018

main subject

phase II clinical trial

0 references

bevacizumab

1 reference

based on heuristic

inferred from title

endometrial carcinoma

1 reference

1 reference

1 reference

Fiona Simpkins

1

1 reference

17 May 2018

Richard Drake

2

1 reference

17 May 2018

Pedro F Escobar

3

1 reference

17 May 2018

Benjamin Nutter

4

1 reference

17 May 2018

Nabila Rasool

5

1 reference

17 May 2018

Peter G Rose

6

1 reference

17 May 2018

language of work or name

English

0 references

publication date

6 December 2014

1 reference

17 May 2018

published in

Gynecologic Oncology

1 reference

17 May 2018

volume

136

1 reference

17 May 2018

issue

2

1 reference

17 May 2018

page(s)

240-245

1 reference

17 May 2018

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

pRb2/p130 and VEGF expression in endometrial carcinoma in relation to angiogenesis and histopathologic tumor grade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Trends in endometrial cancer incidence rates in the United States, 1999-2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Relationship between the classification of vascular invasion severity and the prognosis of uterine endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

Markers of response for the antiangiogenic agent bevacizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.12.004

10.1016/J.YGYNO.2014.12.004

7 January 2021

Identifiers

DOI

1 reference

17 May 2018

PubMed ID

25485782

1 reference

17 May 2018